Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Clinical Genitourinary Cancer
|
November 6, 2023
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma
James Schuster, Iris Y Sheng, Chandana A Reddy, et al.
Clinical Genitourinary Cancer
|
August 29, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab
Moshe C Ornstein, Laeth George, Wei Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
Anita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
Eric Jonasch, Rebecca S Slack, Daniel M Geynisman, et al.
Clinical Genitourinary Cancer
|
March 27, 2018
Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
Vadim S Koshkin, Pedro C Barata, Lisa A Rybicki, et al.
European Urology
|
January 4, 2022
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al.
Clinical Genitourinary Cancer
|
December 25, 2025
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy
Monica S Nair, Jessica Scarborough, Chandana A Reddy, et al.
Journal for Immunotherapy of Cancer
|
January 31, 2018
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Vadim S Koshkin, Pedro C Barata, Tian Zhang, et al.
The Lancet. Oncology
|
August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
Moshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Clinical Genitourinary Cancer
|
November 6, 2023
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma
James Schuster, Iris Y Sheng, Chandana A Reddy, et al.
Clinical Genitourinary Cancer
|
August 29, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab
Moshe C Ornstein, Laeth George, Wei Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
Anita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
Eric Jonasch, Rebecca S Slack, Daniel M Geynisman, et al.
Clinical Genitourinary Cancer
|
March 27, 2018
Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
Vadim S Koshkin, Pedro C Barata, Lisa A Rybicki, et al.
European Urology
|
January 4, 2022
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al.
Clinical Genitourinary Cancer
|
December 25, 2025
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy
Monica S Nair, Jessica Scarborough, Chandana A Reddy, et al.
Journal for Immunotherapy of Cancer
|
January 31, 2018
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Vadim S Koshkin, Pedro C Barata, Tian Zhang, et al.
The Lancet. Oncology
|
August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
Moshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Page
of 7